| abstract |
The invention relates to the use of an Egr-1 transcription factor polypeptide or anbiologically active fragment thereof, and to nucleic acid molecules encodingnsuch polypeptides, in the manufacture of a medicament for the treatment ofnwounds in a mammal, including human. In addition, it relates to a sequencenthat is believed to include important regions involved in the transcription of thentranscription factor Egr-1 in humans and in the regulation thereof. Thisnsequence can be used to design appropriate nucleic acid molecules andnvectors that can be used in the treatment of wounds, as well as in otherntreatment. |